Who's going places in the outsourcing world?

By Zachary Brennan contact

- Last updated on GMT

Who's going places in the outsourcing world?

Related tags: Executive officer, Chief executive officer, Management occupations

A number of outsourcing companies are shifting and adding to their executive decks. Here's a roundup of a couple new moves:

Pacific BioLabs

Californian contract research organisation (CRO) Pacific BioLabs has appointed Michael Yakes as head of Toxicology Testing Services.

The CRO performs GLP and GMP research, as well as medical device studies Yakes will be responsible for all toxicology, PK/ADME, bioassay, and biocompatibility testing.

The appointment comes after 14 years in the pharma industry. Yakes directed pharmacology programmes and managed a team of 44 researchers at Exelixis, and was Senior Director of Translational Biology for Cleave Biosciences, overseeing toxicology, DMPK, and pharmacology testing.

West

West Pharmaceutical Services has appointed a new CEO in the shape of ex-Sigma-Aldrich exec Eric Green. The company provides drug delivery services for injectables companies

Green joins West from Sigma-Aldrich, where he served as Executive VP and President of Research Markets – a $1.4bn business unit – for the last two years. He succeeds current CEO Donald Morel, who will remain Chairman until July.

Grand River Aseptic Manufacturing

Contract manufacturing organisation (CMO) Grand River Aseptic Manufacturing has appointed Tom Ross CEO. He has served as President of the company since 2013.

He previously worked for generics manufacturer Perrigo and for management consultancy DWH.

Halocarbon

Halocarbon Products Corporation, a producer of specialty fluorochemicals and inhalation anesthetics, named David Bacon as its new chief executive officer, effective April 28, 2015.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars